Finance

Lists
Q1 2027 earnings • released • EPS miss -1.10% • Revenue beat +2.60%
See results
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2,285.00
+0.66%
(+15.00) 1D
Aug 7, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2,274.90
High
₹2,289.00
Low
₹2,256.00
Mkt. cap
644.83B
Avg. vol.
578.53K
Volume
437.61K
Dividend
0.22%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
47.37
52-wk high
₹2,474.00
52-wk low
₹1,792.60
EPS
₹48.24
Shares outstanding
0.00
No. of employees
16K
Open
₹2,274.90
High
₹2,289.00
Low
₹2,256.00
Mkt. cap
644.83B
Avg. vol.
578.53K
Volume
437.61K
Dividend
0.22%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
47.37
52-wk high
₹2,474.00
52-wk low
₹1,792.60
EPS
₹48.24
Shares outstanding
0.00
No. of employees
16K
News stories
From sources across the web
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees15.8K
FoundedNov 18, 1977
Headquarters-
SectorPharmaceutical industry
Websiteglenmarkpharma.com
Last report
Aug 2, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹17.11 / ₹17.30
-1.10%miss
Revenue / Est. (INR)
40.18B / 39.17B
+2.60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
60.47B
39.01B
37.71B
40.18B
Cost of goods sold
12.65B
12.95B
11.72B
12.46B
Cost of revenue
12.65B
12.95B
11.72B
12.46B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.86B
8.41B
8.87B
9.35B
Operating expense
25.64B
18.90B
19.84B
21.41B
Total operating expenses
38.29B
31.85B
31.56B
33.87B
Operating income
22.18B
7.15B
6.15B
6.32B
Other non operating income
2.01B
444.65M
1.89B
657.64M
EBT including unusual items
9.67B
5.34B
3.88B
6.43B
EBT excluding unusual items
23.53B
7.18B
7.61B
6.43B
Income tax expense
3.57B
1.31B
864.49M
1.61B
Effective tax rate
36.90%
24.49%
22.29%
24.96%
Other operating expenses
13.37B
8.94B
9.48B
10.33B
Net income
6.10B
4.03B
3.01B
4.83B
Net profit margin
10.09%
10.34%
7.99%
12.02%
Earnings per share
-
19.21
20.96
17.11
Interest and investment income
-
-
-
-
Interest expense
-664.63M
-414.32M
-426.04M
-539.97M
Net interest expenses
-664.63M
-414.32M
-426.04M
-539.97M
Depreciation and amortization charges
1.41B
1.54B
1.48B
1.73B
EBITDA
23.54B
7.80B
7.58B
7.75B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps